The Cure for Cancer is in Space
Scientists have known this since Einstein.
But making medicine in zero-gravity has been impossible — until now.
Find out why you could make 600%+ in the weeks ahead.
PLUS: You’ll also discover why Trump just hired this space firm for NASA's Mars Missions (and why this will lead to stratospheric gains for investors).
Today I’d like to make an announcement that may seem outrageous...
Or too good to be true...
But I assure you, it’s backed by the most important science minds of our generation.
It’s also the subject of intense interest from the world’s most influential investors.
So here we go:
A new scientific breakthrough could make it possible to live 20, perhaps even 30 years longer than is possible today.
And this same breakthrough could also solve...
- Aggressive cancers — making them disappear completely in a matter of months, saving tens of thousands of lives every year
- Autoimmune disorders — giving patients a new lease on longevity
- And antibiotic-resistant viruses — the so-called “superbugs” that continue to kill more and more Americans. This breakthrough could hit “superbugs” so hard that millions of people would instantly see improved quality of life
I’m talking about the “end of death” as we know it.
Or the Death of Death, if you will.
Now before you click away from this video, or dismiss me as some quack who’s promoting some new crackpot medicine...
It’s nothing like that.
I hope you’ll hear me out, because I promise this isn’t what you’re expecting.
What you’re going to hear over the next few minutes has nothing to do with some hard-to-understand medical terms, or a bunch of formulas, or endless quotes from doctors and research studies you’ve never heard of.
I’m not going to drone on about FDA approvals or longshot drug trials.
What I’m going to tell you about today is actually quite simple.
And it could change every single thing humans know about medicine — forever.
As you’ll hear today, even a small amount of success could add decades to your life.
Some of the biggest names in medicine are already on board.
And thanks to their billions of dollars in funding, it could also make early investors wealthy.
And I mean truly wealthy... we’re talking returns on a magnitude that are truly out of this world.
Okay, enough waiting.
Everything I’ll explain today has to do with one single word.
It’s a word you’ve heard of before.
And that word is...
Gravity.
Gravity is the single-biggest problem for traditional medicine — it’s what’s keeping down new discoveries.
It’s quite literally forcing new scientific discoveries to stay grounded, and keeping them from producing new, life-extending medicines.
Gravity is the destructive factor that’s literally crushing the next generation of miracle drugs.
And then, here’s the real kicker...
Scientists don’t need to make any new drug discoveries for this breakthrough to work — because these medical compounds already exist!
Scientists have literally thousands of medicines, cures, and life-extensions that have already been discovered.
Their formulas are all written out.
The research papers discussing their use have already been published, many for decades now.
Some for 50 years or more.
But gravity has kept all of these next-generation medicines from getting off the ground.
Scientists can easily draw out these compounds on a whiteboard... and they’ve been doing so ever since Einstein was alive.
But these compounds have remained impossible to make in a lab on Earth, where gravity breaks down their chemical bonds.
You see, on the molecular level, gravity changes the way sensitive compounds bond to each other.
Gravity has made it impossible to make all of these new life-saving medicines.
That is, until now.
So here’s the breaking news that led to this video here today:
Even though it’s impossible to make these compounds on Earth, they’re easy to formulate in the low-gravity environment of space.
In space, and the low-gravity environment where satellites orbit, these new compounds can finally be produced.
Companies like Merck are already making billions.
And ultra-wealthy investors like Jeff Bezos, Elon Musk, and Bill Gates are already buying up their stake.
New drugs are already in production.
As Wired Magazine put it in a recent article: “The Next Generation of Cancer Drugs Will Be Made in Space.”
And then there’s Bloomberg, which recently declared that the “next blockbuster drug might be made in space.”
As you’ll hear over the next few minutes, the commercial space firm that’s behind these innovations has already produced several new medicines and returned them to Earth, where they’ve already made a life-saving difference for patients.
But this is only the beginning.
I’ve just returned from a fact-finding trip to Washington DC and Northern Virginia, where I was able to see this space firm’s launch site in person.
This commercial space firm is about to expand their space medicine program — and early investors have a lot to gain.
In fact, I’ve already made triple-digit gains on this company.
But there’s a lot more to come.
And here to help me explain why is my friend and colleague Chris Curl.
He’s my co-editor for our tech-focused publication, Digital Dispatch.
He’s been busy researching the other half of this story, which includes a trip to Austin, Texas, where he visited the construction site of this space firm’s biggest competitor...
SpaceX — the $350+ billion private company owned by Elon Musk.
SpaceX’s value is an important benchmark because they show just how much the space industry is worth... and how the potential for us as investors stretches into the stratosphere and beyond.
JOHN:
Chris, thank you so much for taking the time to join us.
CHRIS:
Thank you, John, I’m happy to be here.
As you said, SpaceX and its valuation, which is $350 billion and counting, proves just how lucrative the space industry has become.
In fact, SpaceX is now the largest and most expensive private company in the world.
And everybody wants a piece of it.
Wall Street is desperate to buy shares of SpaceX, but they can’t... because it’s a private company and it’s tightly controlled by Elon Musk.
“How to buy shares of SpaceX” is even one of the most-searched terms on the internet.
It’s something everybody wants in on — many people watching may be among them.
Which, I get it...
The whole reason we’re making this video today is because of the space industry’s rapid growth.
But in my opinion you’re wasting your time and money if you’re holding out for SpaceX.
I don’t think it would be worth it to buy shares of SpaceX, even if you could.
That’s because there’s a much better deal out there for investors...
And that’s the small space firm we’re talking about today.
When you compare valuations, shares of this small space firm are a much, much better deal, and they’ve got an entire universe of room to grow their market share.
They’re already reaping the benefits of Wall Street’s pent-up demand — and this is only going to increase as the space industry grows.
Today you’ll hear why this small space firm is competitive with SpaceX in every single way.
And then, most important for our purposes here today, you’ll hear why this company also has a massive extra benefit that SpaceX doesn’t have...
As you said earlier, John, this small space firm is the only company in the world with the technology to help pharmaceutical companies produce medicines in space.
Few investors are prepared for what’s coming — but that’ll change very quickly as these medical discoveries come to market one after another.
Again, scientists have known about them for decades... and now it’s finally possible to produce these life-saving medicines beyond the reach of gravity.
Because there’s one thing that can be said for sure: the cure for many cancers is up in space.
Scientists already know this.
And life-changing drugs for Alzheimer's, cures for auto-immune disorders, for Parkinson's... they’re all in space.
And get this, it’ll likely also be space medicine that saves us from the antibiotic-resistant “superbugs” that kill millions of people every year across the globe.
It’s a big statement, but it’s not too far-fetched to say that space medicine is the breakthrough that’ll allow science to cure dozens of diseases, forever.
It could even one day soon bring a stop to death altogether — chemistry says it's possible, given the right advances in space medicine.
But the point for our purposes here today is that these advances are all arriving soon.
And at the very least, it could add years, even decades to the lifespan of every single person watching.
It’s all happening now.
JOHN:
That’s right, timing is everything.
As you’ll hear today, nobody was going to space for so long.
Space exploration had come to a complete halt — especially here in America, when the US discontinued its shuttle program over a decade ago.
Commercial space firms have moved to fill in this gap, and as you’ve likely seen in the news, they’ve done so with great success.
Now there are hundreds of rocket launches every year.
McKinsey says that commercial space will even hit $1.8 trillion by 2035.
And this small space firm is ahead of everyone else in its potential — especially when compared to its share price.
As you said, Chris, they’re competitive with SpaceX in almost every way, and they have a corner on incredible, breakthrough innovations like space medicine.
In fact, SpaceX has been losing engineers to this small space firm in droves.
Many of their greatest minds have been driven out by Elon Musk’s overbearing demeanor.
And so they’ve taken their talent somewhere it's appreciated, where their innovations are taken seriously.
It’s why this firm...
- Has a better safety track record than SpaceX
- Is the only company in the world to achieve an unbroken string of successful launches in just six years
- And why they’re likely going to be the first company to get a heavy-payload rocket into space. Even before Elon Musk and Jeff Bezos
And of course, they’re the only company that can actually change lives, right here, right now, by adding space medicine to this equation.
And then, here’s the best part for you and me as investors...
You’ll hear why we won’t have to wait around to make returns.
The growth is already here, right now.
It happened yesterday, today, and is most likely where we’ll see the biggest growth tomorrow.
Many might find this surprising, but the biggest returns in Chris and I’s Digital Dispatch portfolio haven’t come from AI, crypto, or cloud computing.
Even though we’ve made triple-digit returns on these major trends, some of our biggest returns so far have come from space stocks.
And we’ve seen these giant returns in the past 12 months, including...
- 300%+ on a rocket supply firm
- And 600%+ on a satellite production company
Commercial space stocks have continued to deliver for us and the investors who follow our research.
And space medicine is going to ignite a new round of profits for those investors paying attention.
CHRIS:
The pharmaceutical industry has certainly been desperate for innovation.
According to a new report from DeLoitte, Big Pharma has $100 billion worth of drugs in its development pipeline.
Any advances that can help move this along would reap incredible benefits.
Space medicine can do all of this and more...
Reaping the Rewards from the Final Frontier
Because not only can new medicines be manufactured, but existing medicines can also be improved.
I have the perfect example.
Pharma giant Merck was one of the first companies to prove what’s possible in low gravity.
In 2017 and 2019 they completed a series of low-gravity space experiments to try and create a new formulation of their cancer drug Keytruda.
These experiments were an outstanding success, and the results were published in the prestigious science journal Nature.
You can see the published diagram of the low-gravity chemical bonding right here.
Now I’m no chemistry expert, and so I’m not really sure what to make of this diagram.
But the peer-reviewed commentary published in Nature claims success across the board for the goals of this study.
It’s greatly enhanced the efficacy of Keytruda, and it’s made it a superstar drug for Merck.
This important drug has now been taken by over a million patients and improved their lives with better health outcomes.
It’s also been a commercial success, and it continues to generate $20 billion in sales every year.
Those are some big numbers.
And they were only made possible by those vital space experiments.
What Merck saw with Keytruda is just the beginning of what’s possible.
And pharma giants are putting enormous investments into advancing this science.
But here’s the thing...
The Merck experiments all took place on the International Space Station.
And the lab results had to be directly monitored and conducted by astronauts.
While it proved what’s possible chemically in a low-gravity environment, it also highlighted the extreme shortcomings of this kind of space work.
That’s right.
It’s worth reminding everyone, the International Space Station is scheduled to be decommissioned in 2030 — so it’s not even going to be an option for much longer.
And it’s gotten harder, and more expensive, to get astronauts and lab equipment to and from the space station.
It takes months, if not years of planning.
And spots are so few, making it all but impossible for most drug companies to get their experiments on the list.
There have also been other disastrous shortcomings from these human-led missions.
I’m sure you’ve heard about the two astronauts who were unexpectedly stuck at the space station.
Their eight-day mission turned into more than eight months when their Boeing capsule wasn’t able to make the return journey.
NASA faced a barrage of negative press.
But worst of all for pharmaceutical companies, this was just one of many SNAFUs that disrupted their schedule for space medicine experiments.
Human-assisted experiments face too many delays, failures, and interruptions to be reliable.
So despite the billion-dollar success Merck saw with Keytruda, the unfortunate conclusion is that using a manned space station for this kind of work is both limited and outdated.
It’s never going to get the job done.
That’s why the commercial space firm we’re following has created such a breakthrough.
It uses specially-designed space capsules, all of which cost just a fraction of what’s required to send humans to the space station and keep them alive and healthy while up there.
These space capsules are smaller, cheaper, and automatic.
They can be put into space in a fraction of the time — in many cases it’ll only take them a few weeks to produce their payload of medicine.
And then, most important of all, let’s bear in mind that ultimately it won’t be experiments that have the biggest impact.
The biggest impact will come from actually producing these drugs in the low-gravity environment...
And at a volume that would be completely impossible for human astronauts to manage or to produce in any other way.
We’ll give you a quick overview of how it works.
How Space Will Bring Us the Next Generation
of Medical Breakthroughs
JOHN:
Yes, let’s take a quick tour of this company’s 100,000-square-foot factory floor.
They assemble all kinds of vehicles and satellites in here (spoiler alert: they’re even building two Mars orbital satellites for the missions announced by Trump’s Mars missions.)
But the most important project of all is this space medicine capsule.
As you can see in these photos right here, all of the magic happens inside a self-contained capsule.
It’s about three feet in diameter, and is loaded with just under 300 lbs of electronics and drug manufacturing equipment.
STEP ONE
The space capsule is launched into space on one of this company’s rockets.
They have three different company-owned launch sites to choose from, including a new facility in Virginia that I recently saw.
At present they use small rockets, but one day they’ll also use larger rockets that can handle even larger payloads — they can pack them full of dozens of these capsules.
STEP TWO
As soon as the rocket reaches orbit it’ll release the space capsule.
The rocket will return to Earth, where it can land and be used again and again — as I said earlier, this company has a flawless launch history, a success rate that’s better than SpaceX, and the best safety record of any space company.
STEP THREE
The capsule will orbit in the low-gravity of space and the life-saving medicine will be produced inside using automated robotic mechanisms. At present this takes several weeks. But one day it may take just days or hours, depending on the requirements of the formula.
STEP FOUR
The space capsule de-orbits, and then re-enters the Earth's atmosphere, where it parachutes to its landing site with its payload of medicine safely intact.
This space firm has completed a number of successful round trips so far.
For example, their very first capsule made three batches of a new HIV antiviral drug that requires delicate compounds assembled in low gravity so it can treat AIDS.
Scientists have known about this drug compound for decades — but it’s only now, in the last few months, that it’s been possible to produce it.
HIV patients will finally be getting a new lease on life thanks to what this drug can provide.
But this is truly only the beginning.
These first trips could one day soon become dozens...
And then hundreds...
And then thousands.
As decades upon decades’ worth of drug discoveries can finally be produced in the low-gravity environment of space.
The success of this program has already attracted a number of fans.
One of the partners of Peter Thiel’s Founders Fund said: “I’ve been thinking about this idea around microgravity manufacturing for almost a decade.”
And that’s what led him to convince Peter Thiel and other billionaire backers to put money into the first trips.
As you’ll likely recall, Peter Thiel is the famous angel investor behind PayPal, Facebook, and he’s helped found other tech companies like the cybersecurity firm Palantir.
We’re fans of Thiel’s insights into tech, because we were able to use them to make 335% on Palantir.
This is an actual closed return in the Digital Dispatch portfolio.
And this space firm is giving us a rare opportunity to invest alongside him in this venture.
It’s also a rare opportunity to advance the biggest breakthrough in medicine in decades.
CHRIS:
Yes, as we’ve said, all kinds of new breakthrough drugs could become possible: cures for cancer, Alzheimer’s treatments, solving auto-immune disorders... all of these and more are on the list for future production.
In fact, it’s truly not far-fetched to say that your life could one day be extended by years, even decades, by these new drugs that’ll be produced in space.
You’re fortunate to be living in a time like this.
There are 3 big reasons why this is such a unique moment.
We’d like to quickly take you through the 3 major catalysts that are igniting the growth in space stocks — and why this one commercial space firm is in the perfect position to reap the lion’s share.
JOHN:
Without a doubt.
And there’s a reason it’s all happening now.
So let’s get right into it, beginning with...
Catalyst #1: Space Launches Are Finally Frequent Enough to Support a Medical Program
This is a unique time in history.
There are finally enough rocket launches to support a medical program.
Let me show you what I mean.
In 2024 the number of successful rocket launches surged past 200, which is already more than double the number of launches from just a decade ago, as you can see in this chart right here.
And the number of satellites launched is even more dramatic, as rocket capacity has grown, with each launch capable of releasing more and more satellites.
There are now more than 2,000 satellites put into space each year, which is far beyond what even seemed possible just a short time ago.
In fact, there were more satellites launched into space in the past five years than in all previous years combined... even if you count all the way back to October of 1957, when Russia first put Sputnik 1 into orbit.
And the commercial space firm we’re following made sixteen of these rocket launches, all successful, all completing their mission.
They also successfully completed engine tests of two upcoming larger rocket models, which will greatly expand their payload capacity — and will keep this space firm well ahead of any competitors.
These larger rockets will make it possible to send hundreds, if not thousands, of space medicine satellites into low-gravity orbit.
This commercial space firm has spent the last several years developing their reusable booster rocket system, which greatly lowers the cost of launches and shortens development time.
Apart from SpaceX, they’re currently the only company in the world with a fully reusable rocket system.
And they’re the only company other than SpaceX and Jeff Bezos’ Blue Origin to have a reusable heavy-payload rocket.
They’re redefining the limits of what’s possible for America’s future space program.
CHRIS:
Yes, that’s right.
And that’s the perfect segue, which brings us to...
Catalyst #2:
Space Is Once Again A National Priority
Innovation in the space program has been dormant for far too long.
And our industries have suffered because of it.
America was once the undisputed leader of space exploration and space innovation.
The moon landing is the most iconic event in America’s history — and marks the defining moment when the US accomplished what nobody else could.
But we’ve given up a lot of that early lead to Russia, China, and the European Union.
And technologies that we used to build easily have now been mothballed.
The companies that built them have gone under.
Just a few years ago, nobody was going back to space.
The Trump administration has finally changed all of that.
While we’re not fans of Trump in so many ways, including many of his political entanglements, we think Trump’s support for the space industry has been one of the best things to come out of this election.
Because, to put it another way: America can’t be great without space.
And space is finally getting the priority it deserves.
Trump created the US Space Force during his last administration.
And we’re seeing more momentum now than ever before.
It’s directly benefited our Digital Dispatch portfolio.
And it’s brought a raft of support to the small space firm.
They have a $5.6 billion contract to supply Space Force with its new lineup of rockets.
And they’re crucial to expanding the frontier of what’s possible.
Trump said in his inaugural address that he wants: “to plant the stars and stripes on Mars.”
This small space firm is building the critical first step.
As you can see in the photos here, NASA hired this firm to build two Mars orbital satellites, which will provide key data that could one day make a manned mission to Mars possible.
These satellites will orbit Mars and provide vital communications, weather information, and data relays.
A Mars mission would be impossible without these satellites... and it’ll be the very first time satellites have ever been put in orbit around another planet.
The small space firm was the vendor of choice for this highly advanced project — and it’s one more example of where this company has outperformed SpaceX.
In fact, this space firm has repeatedly proven they can pull off feats no other company can.
We saw one key example of this last year, when they built an entire specialized satellite system from scratch in just ten weeks.
The exact details are unfortunately classified, as this project was for a government agency, but they revealed during their quarterly presentation that they were able to go from a signed contract and printed blueprints to a completed vehicle launched and orbiting the Earth, all in 70 days.
Not even Elon Musk can turn around projects with that kind of speed and accuracy.
And then most important of all, it’s also why this is the only company in the world that can bring us space medicine.
JOHN:
That’s right.
The world’s pharmaceutical companies are standing by.
Which brings us to...
Catalyst #3: Big Medicine Has Deep Pockets
And Is Ready to Spend
You heard earlier about Merck’s success with Keytruda, which improved patient outcomes and has now been taken by a million Americans.
It generates $20 billion in sales every year — all because of space medicine.
Bristol Meyers Squibb has seen similar successful results from their space medicine experiments.
And so this space firm hasn’t had any trouble finding partners in the pharmaceutical industry.
They haven’t released their current client list — that’s classified.
But we do know that every company on the list is a significant player.
As one project director said during a recent quarterly earnings call:
“We are primarily focused on the top 20 pharma for clients... Across those companies, there’s actively about 2,000 drugs being worked on.”
As you heard earlier, according to DeLoitte, we know that those companies have a combined $100 billion worth of drugs in their pipeline.
Space medicine will be the platform that can finally drive these life-saving medicines forward.
Those are the 3 catalysts driving this space firm’s stock forward.
Here’s why this is so exciting for us as investors...
This space firm’s stock price is extremely undervalued given all they’re doing.
At the current share price, the market cap of this space firm is $15 billion.
While impressive for a small firm, it proves they’re a steal.
For comparison, we don’t have to look far.
SpaceX is the one and only benchmark that insiders are using.
And SpaceX is currently valued at over $350 billion.
It’s in fact the most valuable privately-held company in the world, and there’s a wealth of market share that’s open for the taking.
Better Than SpaceX, At A Fraction of the Price
This company has benefitted from the success of SpaceX, and as their number of rocket launches continues to increase, they’ve been catching up.
As its CEO recently said in an interview:
“So as we continue to execute, the gap between our two businesses continues to shrink more and more and more. We’re currently valued at less than 5% of SpaceX, but give it a few more years.”
This commercial space firm is an outstanding deal, especially when you consider...
- They have a better success record than SpaceX
- They have a better safety record than SpaceX
- They have a wider variety of rockets and mission capabilities
In short, you can get SpaceX-level exposure at a tiny fraction of the price.
And no other competitors are even close.
CHRIS:
This space firm is also the only company other than SpaceX that can make their own satellites at scale.
And then, as we’ve highlighted today, they’re the only commercial space firm in the world with the capabilities to fully accommodate space medicine.
And if Elon suddenly decides he wants in on the space medicine business?
Even better — this company has such a solid head start that they’ll ride even higher on the waves created by the news.
Everything you need to know is in your special report.
JOHN:
The research in this special report is truly impossible to find anywhere else.
Your report includes:
- The name, ticker symbol, and precise buy recommendation for this commercial space firm
- 100% original research on this unique company that you can’t find anywhere else, including our breakdown of their launch schedule, contract pipeline, and financials. It also includes access to quotes from the company’s CEO and management team
- An overview of the space medicine program and Big Pharma’s plans for new, low-gravity produced drugs
CHRIS:
And then most important of all, it includes our insights on how to make the most of this opportunity as investors.
Our readers have been able to make triple-digit gains on previous reports we’ve published.
One of these readers, named Zach T, wrote this to us last year:
“Just reaching out to say thank you... I was thrilled to walk away with a 300% gain in just 4 months. Thanks for the recommendation!”
— Zach T, Eau Claire, WI
It’s our goal to show you returns like these.
JOHN:
The research report is invaluable and could easily lead to 600%+ gains or higher, just as we’ve seen before from the commercial space front.
We’d like to rush you a copy right away.
And best of all for you today, we won’t charge you anything extra to read it for yourself.
All we ask in return is that you try out our research service Digital Dispatch...
Because discovering profitable investment opportunities like this is exactly what our research is all about.
When you click the button below, you’ll be taken to a short order form that shows you how to get started...
Including an introductory low price that’s just for you.
It’s simple, straightforward, and takes just a minute.
CHRIS:
That’s right.
And you’ll get full access to all of the opportunities in our investment research service Digital Dispatch.
The point of our service is to make sure that you’re never left behind.
Over the past 40 years, tech has consistently outperformed every sector of the market.
It’s where the biggest returns come from — and we’re here to show you how, when, and where to make the best of them a part of your portfolio.
The moment you become a subscriber you’ll receive...
- A new issue every month
- A complete model tech portfolio
- Breaking-news alerts
- A Quarterly Tech Summit, where we discuss a new topic and answer your questions
- And our Tech Trends dashboard, which is right on the homepage of the Digital Dispatch website
You’ll be able to benefit from our tech insights right away.
We have more than a dozen open positions in the Digital Dispatch portfolio that are showing us positive gains, including 79% on an AI services company, 106% on an AI and robotics company, and 135% on a bitcoin mining company.
JOHN:
As Chris said, we’ve been investing in the tech industry for more than 20 years.
And we’ve seen a host of gains from every area of technology, making early wins on Apple, AOL, Cisco, Tesla, and Netflix, long before they were popular with most investors.
We’ve continued this track record with Digital Dispatch.
At the beginning of 2023, with AI’s growing importance on the horizon, we wrote a special report recommending that our readers buy Nvidia — this was BEFORE it became major news... and we were well ahead of the crowd.
The rest of Wall Street came piling in once the word was out, giving us a gain of 663%.
That’s an actual closed return in the Digital Dispatch portfolio.
And then we also made 335% on the AI / cybersecurity firm Palantir, once again getting into the stock before Wall Street.
We believe that the commercial space firm in our new report has everything it needs to deliver similar returns.
But there’s still a lot more to this offer.
When you become a VIP member with a two-year membership, you’ll also receive TWO MORE reports.
As we’ve seen, the growth in technology is creating change in almost every industry… and these two bonus reports will show you additional profits.
These two VIP bonus reports are focused on AI, where we’ve seen gains of 123%, 149%, and 235% in the past few months.
And now that America is going to head-to-head with China in an AI arms race, the momentum is picking up speed.
Each of these reports will give you access to the best and brightest America has to offer in this showdown of AI superiority.
Let me give you a quick overview of each one.
There’s VIP Bonus Report #1: “The Silicon Trail to AI Profits.”
We’re following the silicon…
As Mark Twain famously quipped:
“When everybody is digging for gold, it's good to be in the pick and shovel business.”
In this AI gold rush, chips and wafers are the new picks and shovels. It’s impossible to mine new AI discoveries without them — and chip makers are well-positioned to get paid first.
The company in this report is essential to the chip industry.
This company holds 19,180 patents, and they sell and lease their technology to Intel, AMD, TSMC, Samsung, ARM Holdings, and of course, Nvidia.
This report is a must-read for making money on AI.
And there’s VIP Bonus Report #2: “AI Buyout Frenzy.”
We’re following all of the money that continues to pour into AI…
According to McKinsey, AI is growing from a $95 billion niche sector to a $4.4 trillion megamarket.
Big Tech is racing to keep up, and in order to get ahead, they’re willing to buy up any small AI firm they can find.
The world’s largest companies have spent billions of dollars on more than 115+ new buyouts…
Often paying up to $21 million per employee.
Bill Gates came out of retirement to help Microsoft keep up.
And Sergey Brin was forced to hurry back to his office at Google, which he hadn’t visited in years.
And then on top of all that, Apple is secretly buying up every AI firm they can find.
There are 3 AI firms at the top of everyone’s buyout list.
The race is on.
This bonus report will reveal all the details you need to profit on this billion-dollar market shift.
We’ll rush you copies of both reports the moment you click the button below.
I think you'll be pleased with what we’ve put together — and you’ll have all of this valuable research in your inbox today.
CHRIS:
We’re excited to show you what’s in store.
As you’ve heard today, it’s the opportunity to buy performance that exceeds SpaceX, at a fraction of the price.
- They have a better success record than SpaceX
- They have a better safety record than SpaceX
- Their satellite production facility is the only one in the world equipped for space medicine
As their CEO recently said in an interview:
“So as we continue to execute, the gap between our two businesses continues to shrink more and more and more. We’re currently valued at less than 5% of SpaceX, but give it a few more years.”
JOHN:
That’s right.
- This commercial space firm is unrivaled in its launch schedule
- It’s already shown us triple-digit returns
- And it’s the only stock perfectly situated to benefit from all 4 of the major catalysts we’re seeing in commercial space right now
We can’t predict the future.
But we CAN predict the fact that Big Pharma is putting billions of dollars into unlocking the power of space medicine — and only one company in the world can build these custom satellites.
Future cures to cancer, Alzheimer’s, and auto-immune disorders are waiting to be made.
The compounds have already been discovered, now they just need the low-gravity environment of space to be produced.
All of the details are in your special report.
All you need to do to get started is click the button below... and we look forward to seeing you on the inside.
The future won’t wait,
John Carl and Chris Curl
Editors, Digital Dispatch